Ivan Hyep's most recent trade in Bicara Therapeutics Inc. was a trade of 125,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 22 Jan 2026 | 1,882 | 147,237 | - | 3.8 | 7,132 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 22 Jan 2026 | 1,882 | 145,355 | - | 18.2 | 34,162 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 1,882 | 65,462 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2025 | 9,200 | 88,984 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.31 per share. | 22 Dec 2025 | 9,200 | 145,355 | - | 18.3 | 168,492 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 22 Dec 2025 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 17,795 | 163,150 | - | 3.8 | 67,439 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 17,795 | 98,184 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 21 Nov 2025 | 17,795 | 145,355 | - | 18.5 | 330,094 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 605 | 115,979 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 21 Nov 2025 | 605 | 145,355 | - | 18.2 | 10,981 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 605 | 145,960 | - | 3.8 | 2,293 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 09 Oct 2025 | 6,415 | 151,770 | - | 3.8 | 24,312 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 6,415 | 116,584 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 09 Oct 2025 | 6,415 | 145,355 | - | 18.2 | 116,931 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 18,244 | 128,626 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.22 per share. | 06 Oct 2025 | 18,244 | 145,355 | - | 18.2 | 332,386 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 18,244 | 163,599 | - | 3.8 | 69,141 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.17 per share. | 06 Oct 2025 | 6,514 | 145,355 | - | 18.2 | 118,356 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 6,514 | 151,869 | - | 3.8 | 24,687 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 6,514 | 146,870 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 5,627 | 122,999 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.21 per share. | 06 Oct 2025 | 5,627 | 145,355 | - | 18.2 | 102,456 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 5,627 | 150,982 | - | 3.8 | 21,325 | Common Stock |